Created at 10:51 p.m. Aug, 18, 2024
Author:
gpommier
Co-authors:
mohannadkh10
Type of change:
Content error
Rationale for change
Changed from chronic to congestive to accurately reflect the name of the disease that ivabradine treats.
Current
Suggested
Text
Text
Text
Text
Extra
- Indication: reduces hospitalization risk in stable, symptomatic HFrEF (NYHA II-IV) with LVEF ≤ 35%, sinus rhythm, and resting HR ≥ 70 bpm, despite maximally tolerated β-blockers or contraindication to β-blockers
Evidence: Systolic Heart Failure treatment with the If inhibitor Ivabradine Trial (SHIFT) showed:
- 5% absolute reduction in CHF hospitalization
- 2% absolute reduction in CHF mortality after ~2 years of follow-up
Evidence: Systolic Heart Failure treatment with the If inhibitor Ivabradine Trial (SHIFT) showed:
- 5% absolute reduction in CHF hospitalization
- 2% absolute reduction in CHF mortality after ~2 years of follow-up
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Empty field
Picmonic
Empty field
Pixorize


Watch Ivabradine




Watch Ivabradine


Physeo
.jpg)
.jpg)
OME
Additional Resources
Empty field
One by one
Empty field



